Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab plus reduced-dose FC versus obinutuzumab plus chlorambucil in elderly comorbid untreated CLL
ACTRN12614000376640Phase 2Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of obinutuzumab, fludarabine, cyclophosphamide and chlorambucil, sponsored by Australasian Leukaemia & Lymphoma Group. Started Dec 2015; status: terminated.
02
Drugs
obinutuzumabfludarabinecyclophosphamidechlorambucil
Beyond the preview
Go deeper on ACTRN12614000376640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000376640.